Understanding How IL-23p19 Inhibitors Work in Psoriasis

This program will include a discussion of data some of which has only been presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

Introduction

The Role of IL-23 in the Psoriasis Disease Cascade

The Role of IL-23 in the Psoriasis Disease Cascade (cont)

Therapeutic Strategy in Psoriasis -- Difference Between Upstream and Downstream Inhibition

IL-23 Inhibitors in Moderate-to-Severe Psoriasis -- Approved and in Latest Development Stages

Difference Between Ustekinumab (IL-12/ IL-23p40 Inhibitor) and IL-23p19 Inhibitors

Guselkumab vs Adalimumab: VOYAGE-1 and VOYAGE-2

Guselkumab vs Secukinumab: ECLIPSE

Tildrakizumab vs Etanercept: reSURFACE-1 and reSURFACE-2

How Do Guselkumab, Tildrakizumab, and Ustekinumab Compare How Do Guselkumab, Tildrakizumab, and Ustekinumab Compare? -- Expert Perspective

Risankizumab vs Ustekinumab -- ultIMMA & Risankizumab vs Adalimumab -- IMMvent

PASI 90/100 as Endpoints -- Expert Perspective

Mirikizumab: PASI 90 at Week 16 Phase 2 Study

Ranking of IL-23p19 Inhibitors -- Expert Perspective

What Are the Differences Between IL-23p19 and IL-17 Inhibitors?

IL-23p19 Inhibitors -- Insights on Remission and Disease Modifying Effect

IL-23p19 Inhibitors -- Insights on Remission and Disease Modifying Effect (cont)

Durability of IL-23p19 Inhibitors

Difficult to Treat Psoriasis -- Ixekizumab IXORA-S Study in Nail Psoriasis

Difficult to Treat Psoriasis -- Guselkumab NAPSI and f-PGA (VOYAGE-2)

Difficult to Treat Psoriasis -- Risankizumab

Additional Indications Under Investigation for IL-23p19 Inhibitors

PASI 90/PASI 100 and Quality of Life -- What Is the Value for Patients?

Experience Using IL-23p19 Inhibitors -- Expert Perspective

Concluding Remarks

Concluding Remarks (cont)

Abbreviations

Abbreviations (cont)

Abbreviations (cont)